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THE SOCIOLOGY OF PHARMACEUTICALS: PROGRESS AND 
PROSPECTS 
 
Simon J. Williams, Jonathan Gabe and Peter Davis 
 
 
 
Recent years have witnessed an upsurge of interest in pharmaceuticals 
and society, a trend which in part reflects the growing power and 
influence of the pharmaceutical industry over all our lives, qua patients, 
consumers and citizens. Medicine costs the National Health Service 
(NHS) in England alone over £7 billion every year, 80% of which is spent 
on branded (patented) products, with the pharmaceutical industry the 
third most profitable activity in the UK economy after tourism and 
finance (House of Commons Health Committee 2005). These figures, in 
turn, are part and parcel of bigger global picture of pharmaceuticals sales 
which is forecast to grow by 5-6% between 2007 and 2008 to over US 
$735 billion a year -- with North American sales alone constituting nearly 
half of this market, and North American and European pharmaceutical 
sales together constituting over three quarters of global pharmaceutical 
sales (IMS MIDAS 2008 http://www.imshealth.com). Scarcely a day 
goes by, moreover, without some story or other in the media about 
pharmaceutical products and practices. On the one hand, newspaper 
headlines boast new breakthrough ‘wonder drugs’. On the other hand, 
stories of drug crises or controversies are regularly rehearsed in the 
media, thereby stirring fear and fascination in the public mind as to the 
power of pharmaceuticals and the industry that markets and manufactures 
them. Clearly pharmaceuticals have an important role to play in the 
alleviation of human suffering and the saving of lives. They are also, 
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however, the source of much controversy, contestation and conflict, not 
simply in terms of their development, testing and marketing, but in terms 
of their very meaning and consumption. 
 
This monograph is both a reflection of and response to this upsurge of 
interest in pharmaceuticals and society, casting further critical 
sociological light on these developments, discourses and debates. It is 
possible, in this respect, to point to a variety of themes and issues which 
taken together demonstrate both progress in sociological research on 
pharmaceuticals over the years and future prospects. 
 
(i) Medicalisation and Pharmaceuticalisation; doctors, disorders and 
drugs 
 
The first and perhaps most long-standing sociological theme, has centred 
on the role of pharmaceuticals in the medicalisation of society. When 
Illich (1975), way back in the 1970s, talked of the iatrogenic effects of 
modern medicine and how the consumption of medical products helped 
sponsor a ‘morbid society’, a key target of his critique was our ‘over-
reliance’ or ‘dependence’ on drugs as well as doctors. Others more fully 
or squarely located within medical sociology, particularly North 
American medical sociology, have also taken up these themes, albeit in a 
less radical or libertarian way than Illich.  Specific emphasis  has been 
placed by these authors on the expansion of medical jurisdiction and 
control over more and more areas of our lives, in the name of health and 
illness (Zola 1970, Freidson 1970, Conrad and Schneider 1980a,b). The 
role of the pharmaceutical industry within these processes, nonetheless, 
remained a somewhat muted or neglected theme in the medicalisation 
literature of the 1970s through to the 1990s, with sociological attention 
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focusing on the power and influence of medicine in the social 
construction of disease and decisions about its treatment. More recent 
work, however, has begun to reappraise these processes in the light of 
current trends and developments regarding the medicalisation of society. 
Conrad (2007, 2005, Conrad and Leiter 2004), for example, in updating 
his previous work in this area (Conrad 1992, Conrad and Schneider 
1980a,b), has pointed to what he terms the ‘shifting engines’ or ‘drivers’ 
of medicalisation over time -- see also Clarke et al (2003) for a somewhat 
different line or emphasis on transitions from medicalisation to so-called 
‘biomedicalisation’. Whilst the definitional centre of medicalisation 
remains with doctors, Conrad argues, the primary drivers of 
medicalisation now pertain to consumerism, managed care markets and 
developments in biotechnology, including the pharmaceutical industry. 
 
Other more critical commentators (many of whom, significantly, are not 
sociologists), have taken these arguments one or more steps further, 
claiming that what may once have been regarded as medicalisation is now 
best seen as outright ‘disease-mongering’ in which the helping hand of 
the pharmaceutical industry looms large. Critics such as Moynihan 
(Moynihan 2002, Moynhan and Henry 2006, Moynihan et al. 2002) and 
Blech (2006), for example, through a series of case studies, have shown 
how pharmaceutical companies in collaboration or conjunction with 
doctors, pressure groups and the media, are no longer simply 
manufacturers of drugs but of diseases for these drugs to treat! – see also 
Law (2006) on ‘Big Pharma’. A recent issue of the Public Library of 
Science – Medicine, for instance, devoted a whole section to essays on 
this very issue, including case studies of a range of diseases or disorders 
from ADHD (Phillips 2006) through erectile dysfunction (Lexchin 2006) 
and female sexual dysfunction (Tiefer 2006) to biopolar disorder (Healy 
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2006). These critiques, to be sure, are important. Not all forms of 
medicalisation, however, involve disease-mongering. Nor do all forms of 
medicalisation entail pharmaceuticals or processes of 
pharmaceuticalisation. Ideally medicalisation should be considered as a 
value neutral term that simply denotes the making or turning of 
something into a medical matter, the merits of which are open to 
empirical investigation depending on the case in question (Conrad 2007, 
1992). Medicalisation, as such, may have positive and negative or light 
and dark faces, involving both gains and losses for the parties involved.  
 
Whatever the merits of the case for outright disease mongering, one key 
vehicle for the expansion of pharmaceutical markets is of course direct-
to-consumer advertising (DTCA): a development which to date is limited 
to countries such as the USA and New Zealand. On the one hand, this 
may be viewed as an entirely new development or departure. On the other 
hand, an instructive parallel and precursor may be found in the guise of 
patent medicine advertising in the past. Conrad and Leiter’s paper, for 
example, sheds valuable further light on these issues. Taking two 
advertising exemplars as its case studies – the late nineteenth century 
Lydia E. Pinkham’s vegetable compounds for ‘women’s complaints’ and 
contemporary Levitra for ‘erectile dysfunction’ (ED) – instructive 
parallels are drawn by these authors between the patent medicine era and 
the DTCA era. One of the great ironies of DTCA in this respect, Conrad 
and Leiter argue, is that it extends the relationship of drug companies, 
physicians and consumers in ways that rehearse or return us to a situation 
similar to Lydia Pinkham’s day, when the drug manufacturers had a 
direct and independent relationship with consumers. Whilst the 
extravagant claims of Pinkham are now constrained by law, moreover, we 
must also contend with the fact that modern advertising has become far 
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more subtle and sophisticated in its attempts  to persuade or convince 
consumers that its products are the right ones in an increasingly 
competitive pharmaceutical marketplace. The pharmaceutical industry 
and consumers, Conrad and Leiter conclude, are increasingly important 
players in medicalisation, facilitated in part by the advent (or return to) 
DTCA. 
 
Another key factor or player in these medicalising processes, of course, 
as Conrad and Leiter’s paper on DTCA clearly attests, are the media. 
Previous sociological studies, for example, have demonstrated both 
celebratory and critical media discourses on drugs, depending on the 
media, format and drug in question, the relative ‘newness’ of the drug to 
the market, and its ‘newsworthiness’  For example, when benzodiazepine 
tranquillisers were first prescribed in the 1960s they generally received an 
enthusiastic welcome in the UK and US media and were proclaimed as 
heralding a new therapeutic era. As their popularity grew, however, their 
therapeutic value ceased to be newsworthy and a more critical coverage 
developed, drawing on the comments of a small but growing band of 
professional and lay critics.  Initially, in the 1970s, this concern focused 
on claims about their overuse as a `chemical crutch’ for personal 
problems, before shifting in the 1980s and 1990s to claims about these 
drugs’ `addictive’ potential, (Gabe and Bury 1996a, 1996b), with users 
portrayed in the local and national UK press as innocent victims, through 
no fault of their own, who then tried to withdraw and embark on a `return 
journey’ to normality (Gabe et al 1991). Moreover, through these forms 
of mediation and marketing, drugs may come to take on personalities of 
their own, achieving some sort of quasi-mythic or celebrity status in the 
popular imagination, construed or constructed as the archetypal hero or 
villain (see for example Martin 2007, Nelkin 1995).  
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 Some of these issues, for instance, are addressed in Williams and 
colleagues paper on newspaper coverage of the wakefulness-promoting 
drug Modafinil (brand name Provigil).  Constructions of this drug in the 
print news media, these authors show, range from largely uncritical 
endorsement of its clinical applications as a ‘break through’ or ‘wonder 
drug’ for a growing list of sleepiness related conditions, to somewhat 
more cautious or critical coverage of its wider (potential) uptake as a 
lifestyle drug of choice, or in sport or military contexts. Again we see 
here, in the guise of this wakefulness-promoting drug, the now familiar if 
not commonplace rehearsal of concern over the blurring or shifting 
boundaries between ‘treatment’ and ‘enhancement’, and the broader 
articulation of cultural anxieties about a move to a 24/7 society in which 
sleep becomes increasingly optional if not obsolete. A notable feature of 
the paper, in this respect, is the authors preference for the term 
‘pharmacueticalisation’ rather than medicalisation in order to capture 
these concerns in the press: concerns, that is to say, to do with the 
potentially widespread use and uptake of pharmaceuticals for diverse 
purposes which extend far beyond the realms of medicine or the strictly 
medical. 
 
Another prime expression of the mediation of pharmaceuticals, of course, 
concerns the Internet or cyber-space/culture -- see, for example, Miah and 
Rich (2008). This includes not simply access to information on 
pharmaceuticals via Internet searches, but the purchase of 
pharmaceuticals through online or e-pharmacies and the sharing of 
information and support through Internet chat rooms and online forums of 
various sorts (Fox et al. 2005a,b). In these and other ways, new 
opportunities for the mediation of pharmaceuticals are opening up in all 
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our lives, for better or worse, routes that may very well bypass the 
traditional doctor-patient relationship altogether. Some of these issues, for 
example, are taken up in Fox and Ward’s paper on the 
pharmaceuticalisation of daily life -- as with Williams et al’s paper, the 
preference for pharmaceuticalisation over medicalisation is once again 
notable here. Taking as their problematic the new emphasis on lifestyle in 
the production, marketing and consumption of pharmceuticals and 
drawing on a diverse array of sources - including literature from social 
science, economics and health services research, together with their own 
their own research on pharmaceutical consumption – Fox and Ward 
identify two broad processes at work here. First, a domestication of 
pharmaceutical consumption, through computer mediated access and 
consumption within the home, particularly the bedroom and the kitchen. 
Second, the pharmaceuticalisation of everyday life, as pharmaceuticals 
come to be seen by consumers as ‘magic bullets’ for a range of everyday 
daily life problems. The domestication of pharmaceutical consumption 
and the pharmaceuticalisation of life, in this respect, become a complex 
mixture or heady brew of factors, including the biological effects of the 
drug on the body, the legitimacy of the problem or disorder in question, 
the willingness of consumers to adopt the technology as a ‘solution’ to a 
problem in their lives, and the corporate interests of the pharmaceutical 
industry. For these authors social relations surrounding contemporary 
pharmaceutical production and consumption ‘link the world of business 
to the private world of citizens, forging new diseases and treatments from 
the very fabric of daily life’. 
 
(ii) Regulation; Science, Politics and the Pharmaceutical Industry 
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 If medicalisation and pharmaceuticalistion constitute one key strand of 
sociological research on pharmaceuticals and society over the years, then 
the science and politics of the pharmaceutical industry, including issues 
of development, testing and regulation, constitutes another rich seam of 
work. Abraham (2007, 1997, 1995, 1994, 1993, 2002, Abraham and 
Davis 2005, Abraham and Lewis 2002, Abraham and Reed 2001, 
Abraham and Sheppard 1999), for example, has been at the forefront of 
this research over the past 15 to 20 years, documenting through detailed 
empirical case study work and comparative analysis elements of 
controversy and corporate ‘bias’ which, at one and the same time, 
demonstrates the inadequacies of existing regulatory practices and 
procedures, and the need for more rigorous and robust policy 
interventions at the institutional and legislative levels. These include the 
development of independent drugs testing by regulatory authorities, 
increased patient and public representation on regulatory committees and 
more frequent and thorough oversight of regulatory performance by the 
legislature - see also Busfield’s (2007a) recent sociological analysis of 
scientific ‘fact making’ in the clinical trials of drugs and in post-approval 
drugs assessment, and the subsequent Abraham (2007) - Busfield (2007b) 
debate.  
 
Many of these issues were explicitly taken up and addressed by the House 
of Commons Health Committee (2005) Report on ‘The Influence of the 
Pharmaceutical Industry’. Whilst rightly noting how pharmaceuticals may 
be a force for the good in contributing to the health of the nation, the 
report is nonetheless peppered with references to a ‘failing’ regulatory 
system, to ‘lax oversight’ and to practices on the part of the 
pharamaceutical industry which ‘act against the public interest’, given the 
power and influence of marketing forces. Recommendations cover 
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several key areas, including the licensing process, with greater 
transparency and independent assessment of evidence, improved 
Medicine and Health Care Products Regulatory Agency (MHRA) 
mechanisms for restraints on medicines promotion, tougher restrictions 
and greater vigilance to guard against ‘excessive’ or ‘inappropriate’ 
prescribing, and a fundamental review of the MHRA itself.  
 
In revisiting these issues, Abraham’s paper provides both a timely review 
of twenty years of sociological research on pharmaceutical development 
and regulation and a reassertion of the importance of a realist empirical 
research programme for the investigation of these issues, based on the 
notion of ‘objective interests’  -- i.e. the objective interests of 
pharmaceutical companies in profit maximisation and the objective 
interests of patients/public health in the optimisation of the benefit-risk 
ratio of drugs. Drawing on international comparisons of drug regulation, 
Abraham shows how commercial interests have biased the science of 
drug testing and review away from patients and the public in favour of 
the industry: a process, he argues, which is best characterised as ‘neo-
liberal corporate bias’. Far from being the ‘inevitable by-product’ of 
technoscientific progress in pharmaceuticals, moreover, these 
international comparisons are valuable in demonstrating considerable 
scope for improvement. Similarly, the lowering of technoscientific 
standards for drug safety across the EU, US and Japan is not, Abraham 
argues, an inevitable price to be paid for faster development of 
therapeutically valuable medicines, but more plausibly a consequence of 
the international spread of neo-corporate bias in pharmaceutical 
regulation. 
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The gender and sexual politics of pharmaceutical development, testing, 
and regulation adds another important dimension to the picture here. We 
see this very clearly, for example, in Casper and Carpenter’s paper on the 
politics and controversy surrounding initiatives to introduce human 
papilloma virus (HPV) vaccine for cervical cancer in the United States of 
America. These initiatives have, in the words of the authors, ‘animated 
longstanding concerns about vaccination ... and young women's bodies 
and behavior.’ The HPV vaccine, in this respect, raises the spectre of both 
past controversies about vaccination and current political concerns in the 
area of sexual morality. Vaccines, the authors argue, are a distinctive kind 
of pharmaceutical invoking notions of ‘contagion’ and ‘containment’. 
Pharmaceuticals, moreover, develop lives or biographies of their own; 
trajectories shaped at every stage or phase by politics. Viewed in this 
light then, it is not so much the public debates about vaccination as such 
that are the most important dimensions to the story here, but that its target 
is a sexually-transmitted disease, which thereby draws into the debate 
issues of sex, gender and women's bodies that are far more charged. The 
launch of the HPV vaccine in short, these authors argue, appears to have 
‘inflamed’ US health care which in turn has affected plans for marketing 
the drug. This in turn underlines both the struggles provoked by this new 
gendered technology and the every emergent and evolving ‘biographies’ 
of pharmaceuticals themselves, which to repeat, are deeply political. 
 
 
Broader questions also arise at this point about the global nature and 
dynamics of the pharmaceutical industry.  These include debates on the 
‘globalisation’ of medicines control (Abraham and Reed 2003), whether 
or not the pharmaceutical industry is in fact truly ‘globalised’ in the first 
place -- multinationalisation, or westernisation, Busfield (2003) argues, 
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are more accurate terms of reference -- and the growing practice of out-
sourcing or ‘pharming’ out clinical trials to the developing world where 
regulatory standards are lower or looser and bodies are in cheap supply 
(Shah 2007). Important questions need to be asked here, for example, 
about who gets what, when, and where - i.e. the global inequalities and 
injustices spawned through the current system of drugs development and 
distribution.  Of particular significance here is the prioritisation of drugs 
for affluent societies where chronic conditions prevail and lucrative 
markets beckon over other basic life-saving drugs for those in poorer 
parts of the world, many of whom exist on less than a dollar a day 
(Busfield 2007a, Petryna et al 2006, Shah 2007). 
 
One seeming success story on this count, at face value at least, concerns 
the state sponsored national provision of Antiretrovial Therapy (ART) for 
people with HIV in Brazil. Yet, as Cataldo’s paper suggests, based on his 
detailed ethnographic research in a favela (shanty town) in Brazil, the 
universal character of this public health programme is challenged or 
problematised in a number of ways through local definitions of illness, 
problems of adherence to treatment, structural violence, political 
alienation and the lack of perspectives about the future. These 
developments, moreover, echoing other writers (Petryna 2002, Petryna et 
al 2006, Biehl 2004, Rose 2007), point to new or novel forms of socio-
political identification and participation focused around the notion of 
‘therapeutic’ or ‘biological citizenship’.  In particular they raise concerns 
about free access to treatment, the right to health care, and the viability 
and sustainability of public health policies in a ‘developing’ or ‘middle 
income’ country.  
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(iii) Consumption and consumerism; Medicines in the marketplace 
 
A third long-standing strand of sociological research on pharmaceuticals 
concerns what may loosely be termed consumption and consumerism. 
Initial work in this area focused on providing a `social audit’ of the use of 
prescribed medicines in the community (e.g. Dunnell and Cartwright 
1972). In the 1980s and 1990s the focus shifted to exploring the social 
meaning of medications ranging from anti-hypertensives (Morgan 1996) 
to benzodiazepine tranquillisers (Helman 1981, Gabe and Lipshitz-
Phillips 1982, 1984, Gabe and Thorogood 1986) and how such meanings 
were shaped by users’ ethnicity and gender (Cooperstock and Lennard 
1979, Gabe and Thorogood 1986, Ettorre and Riska 1995).  
 
More recently, with the growing sociological interest in consumption and 
consumerism (Rief 2008), attention has increasingly focused on users of 
pharmaceuticals as knowledgeable and reflexive actors, assessing the 
risks and benefits and making informed choices in consultation with 
professionals (Fox 2007, Fox et al 2005a). Such consumerism in turn is 
reinforced by UK government policy which constructs patients as experts 
and exhorts professionals to develop a `partnership’ with their patients 
(Taylor and Bury 2007). These developments are explored in the paper by 
Stevenson Leontowitsch and Duggan, who consider how consumers of 
over-the-counter medicines engage with pharmacists and how 
pharmacists seek to maintain their professional expertise in the face of 
healthcare consumerism. Based on interviews with customers and 
pharmacists, group discussions with pharmacists and tape-recorded 
consultations and observations in two pharmacies, they show how 
pharmacists’ attempts to engage customers in discussions about their 
treatment did not result in a reduction in the importance of 
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pharmaceutical expertise. Instead both pharmacists and customers 
acknowledged the importance of the asymmetry of knowledge between 
them. Nonetheless customers did not always see pharmaceutical expertise 
to be necessary and at times talked about over-the-counter medicines as a 
commodity and treated transactions in pharmacies as no different to those 
in other retail outlets. And pharmacists were aware that they were running 
a business and that they needed to be sensitive to the danger of losing 
trade if they resisted selling a product that a customer had requested.  
 
Sociological work on consumerism is not just focused on individual users 
of health care as knowledgeable and reflexive actors. Attention has also 
been paid to the way in which users act collectively to represent their 
interests as members of self help groups, patient advocacy groups and  
health social movements in the public sphere (Kelleher 2004, Brown et al 
2004). In the case of pharmaceuticals this has involved focusing on how 
health consumer groups – voluntary sector organisations that represent 
the interests of patients – engage with the pharmaceutical industry around 
issues such as the availability of and access to medicines. This provides 
the focus for the paper by Jones. She explores how health consumer 
groups in the UK disclose and manage links with pharmaceutical 
companies in the context of their increasing involvement in the policy 
process. She focuses on claims that companies engage with groups in 
order to try and `capture’ their policy agenda. Drawing on evidence from 
group and industry websites and interviews with representative of 
consumer groups, industry and other health care stake holders she reveals 
that only around a quarter of groups known to receive financial or in-kind 
support openly admit to this. Even so Jones rejects the view that this lack 
of transparency demonstrates that these groups’ policy agenda has been 
`captured’. Rather she points to a coincidence of aims (both sides have an 
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interest in medicines being available), the existence of tacit support for 
guidelines to manage conflicts and the fact that funding from industry 
generally represents only a small proportion of these groups’ income. 
Nonetheless she acknowledges that the lack of transparency as regards 
disclosing funding strengthens critiques of undue influence and may well 
reduce policy makers’ willingness to treat consumer groups as the 
legitimate voice of patients in the policy process.  
 
(iv) Expectations and Innovation; Pharmacogenomics, Regenerative 
Medicine and Beyond… 
 
A fourth and final strand of sociological research has been very much 
taken up with innovative new developments in bioscience, biomedicine 
and biotechnology, including pharmaceuticals, which taken together point 
to or promise reconfigured futures. Rose (2007), for example, in his broad 
survey of this newly emerging field, highlights what he takes to be the 
growing ‘politicisation’ of all life forms, given the rapid pace of 
developments in bioscience, biotechnology and biomedicine at the dawn 
of the twenty-first century. This politicisation covers the morphing or 
mutating of biomedicine through molecularisation, debates around the 
very nature and status of what it is to be ‘human’, the formation of new 
biosocial identities, communities and forms of citizenship, and the 
reconfiguration of the boundaries between normality and abnormality, 
health and illness, treatment and enhancement. Developments in 
neuroscience, for example, including novel forms of 
psychopharmacological intervention or enhancement, raise a host of 
social, legal, ethical, political and economic issues which necessitate 
informed dialogue and debate across disciplinary boudaries and wider 
public and policy making arenas – see, for example, the recent flurry of 
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reports on cognitive enhancement agents (Academy of Medical Sciences 
(2008), British Medical Association (2007), Department of Trade and 
Industry (2005). Psychopharmaceuticals, in this respect, are becoming 
central to the way in which conduct is governed, obliging individuals to 
engage in ‘constant risk management, to monitor and evaluate mood, 
emotion, cognition, according to finer and more continuous processes of 
self-scrutiny’ (Rose 2007: 223). 
These developments in turn encourage us to ask pertinent 
sociological questions about the biopolitics of the future, including 
sociology’s own role in the co-construction or co-production of various 
utopian and dystopian biofutures. Recent research on the sociology of 
expectations, for example, has drawn attention to: (i) the dynamic role 
which expectations play in defining roles, attracting investors and 
building mutually binding obligatons; (ii) how expectations differ 
between various social groups (e.g. scientists, policy communities, 
industry, consumers, public), and; (iii) how the futures they envisage are 
‘contingent’, ‘contested’, ‘embraced’, ‘imagined’, including both the 
‘retrospecting of prospects’ and the ‘prospecting of retrospects’ (Brown 
and Michael 2003) – see also Novas (2001) on the political economy of 
hope.  
The development of new vaccines, for example, is an obvious case 
in point, generating hopes, fears, and a variety of other moral and 
political agendas which both hark back to the past and project into the 
future – see, for example, Casper and Carpenter’s paper discussed above. 
Another key area where these issues are very clearly evident is in relation 
to recent developments in pharmacogenetics and pharmacogenomics (i.e. 
the splicing or hybridization of pharmacological and genetic/genomic 
knowledge in order to predict drug reactions). This is a field of 
considerable hyperbole and hope regarding a new era of so-called 
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‘personalised’, ‘bespoke’ or ‘tailor-made’ medicines, construed as the 
perfect antidote to the ‘one-size-fits-all’ remedies currently on the market 
where side-effects or adverse drug reactions (ADRs) are commonplace. 
Whilst major pharmaceutical industry interest and investment in this area 
is relatively recent (little more than 10 years old in fact), 
pharmacogenetics as a term of reference or organising principle has been 
around much longer, dating back to the late 1950s. These developments, 
moreover, generate a number of concerns from a diverse range of 
constituencies, including potential problems of  ‘over-segmented’ (read 
‘unprofitable’) markets; the proliferation of genetic testing, and; the 
‘racial politics’ of personalised medicine – see Brown and Webster 
(2004), and Sneddon (2000) for useful discussions of some of these issues 
and Hedgecoe (2007) for an illuminating study of the politics of 
pharmcogenetics in relation to Alzeheimer’s and breast cancer. Questions 
also arise as to just how personalised these developments can ever be.  To 
the extent indeed that ‘personalised’ medicine is ever truly possible, then 
as Hedgecoe (2007: 5) wryly remarks, this is best seen as the equivalent 
of purchasing a small, medium or large T-shirt from GAP than of being 
fitted for a smart tailor-made Saville Row suit! 
 
Barr and Rose’s paper sheds further comparative light on some of these 
issues in relation to anti-depressant drugs.  Drawing on their empirical 
study of the views of patients with depression regarding genome based 
therapies for their condition (GENDEP) in eight European countries – 
England, Poland, Slovenia, Italy, Denmark, Germany and Croatia – these 
authors show how discussions of the clinical acceptability of genome 
based therapies for depression cannot be divorced from some of the wider 
issues regarding depression and anti-depressants. This includes a 
commonplace tendency to conflate notions of a pharmacogenomic test for 
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antidepressants with a genetic test for depression, doubts about the 
medical model of depression, and a ‘deep ambivalence’ regarding the use 
of anti-depressant medication. On the one hand, strong hope is expressed 
about new drugs to treat depression. On the other hand, concerns remain 
over the need to take such drugs either now or in the future to manage or 
modify moods. These views in turn are tied up with a belief that 
psychiatric illness is somehow ‘different’ from physical illness and that 
depression carries with it a certain cultural value, including positive links 
to creativity, selfhood and identity. There is then, in short, as these 
authors clearly demonstrate, a great ‘ambivalence’ regarding the personal 
and cultural significance accorded to depression and anti-depressant 
medications which genetic testing is likely to exacerbate rather than 
alleviate. 
 
Another key area of hyperbole and hope concerns current research into 
stem cells: developments which hold out the promise or prospects of new 
treatments for conditions such as Alzheimer’s disease, Parkinson’s 
disease and motor neurone disease, through the cultivation of replacement 
neurones. At first glance this may have seemingly little to do with 
pharmaceutical investments, signifying in fact a direct threat or challenge 
to prevailing drug based forms of treatment in the present or future, 
personalised or otherwise. Yet as Wainwright and colleagues’ paper in 
this monograph suggests, a new paradigm of stem cells research is 
emerging, the ‘disease in a dish’ approach, whereby human embryonic 
stem cells (hES) will be used as ‘tools’ to unravel the mechanisms of 
disease and enable the development of new drugs. It is here, at this nexus 
of regenerative medicine, hESC and pharmaceuticals that a new set of 
problems and expectations are being forged; developments which 
Wainwright and colleagues argue can profitably be understood  in terms 
 17
of Bourdieu’s theoretical concepts of capital, habitus and field, 
particularly ‘expectational capital’ which is derived from this set of ideas. 
Experts’ persuasion practices and strategies, from this perspective, 
advance their interests in this uncertain field; a performative strategy 
which helps stabilise this emerging ‘disease in a dish’ model of 
translational research and new pharmaceutical drug development. 
 
Taken together then, a variety of sociological agendas coalesce around 
pharmaceuticals and society, both old and new, as this introduction 
clearly attests; issues, to repeat, which touch all our lives qua patients, 
consumers and citizens. At a time of reinvigorated debate about the 
political and public faces of sociology (Burawoy 2005, Turner 2004), and 
the biopolitics of life itself (Rose 2007), sociological research on 
pharmaceuticals holds out the potential, promise or prospect of analyses 
which  combine an appreciation of what Wright Mills (1959), in the 
Sociological Imagination, classically described as personal troubles and 
broader public issues of social structure. In potentially holding those in 
positions of power to account, moreover, and in engaging in informed 
dialogue and debate with its publics, sociological research on 
pharmaceuticals admirably demonstrates the continuing importance of the 
discipline to these developments, discourses and debates. The 
contributions gathered together in this monograph, we believe, exemplify 
this promise and potential in an era where the power and force of 
pharmaceuticals to treat or enhance us, and the interests shaping their 
development and distribution, manufacture and marketing, look set to 
grow well into the twenty-first century. 
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